SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3d render of the pole vault crossbar on blue sky background
Earnings
Gilead sets blockbuster bar for Yeztugo’s first full year on the market
With initial patients coming back for their second dose of Gilead’s twice-yearly PrEP injection, the pharma thinks the shot will hit $1 billion in sales this year, serving as “a cornerstone in Gilead’s revenue growth story.”
May 8, 2026
 · 
2 min read
 · 
Tristan Manalac
Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.
Pipeline
Ascendis retreats to rare endocrinology wheelhouse as cancer plans falter
Before discontinuing the asset, Ascendis Pharma was studying onvapegleukin alfa in advanced or metastatic solid tumors, demonstrating a three- to four-month overall survival advantage over historical controls.
May 8, 2026
 · 
2 min read
 · 
Tristan Manalac
Composite photo collage of hand hold magnifier glass research examine secret object question mark secret isolated on painted background.
Manufacturing
FDA pilots AI-informed one-day facility inspections
Implemented as part of a broader initiative to make more targeted and efficient use of inspection resources, the pilot program will use artificial intelligence to enable shorter, focused screenings to complement standard FDA inspections.
May 7, 2026
 · 
2 min read
 · 
Nick Paul Taylor
The white plane flies against the blue sky, leaving a white trail. Vector illustration
FDA
FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit
The FDA turned away Ebvallo in January, taking issue with the design of the registrational trial. In a recent meeting, however, the agency agreed that the study could in fact support the cell therapy’s approval. The news comes a week after the departure of controversial biologics Director Vinay Prasad.
May 7, 2026
 · 
3 min read
 · 
Heather McKenzie
Big fish eats small, takeover of the company. Art collage.
Deals
Angelini inks $4.1B Catalyst buy to enter US rare disease market
Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.
May 7, 2026
 · 
2 min read
 · 
Gabrielle Masson
Illustration showing finger pointing people to leave
Layoffs
Gilead wipes out most of Arcellx workforce
Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder happening in 2027.
May 7, 2026
 · 
1 min read
 · 
Angela Gabriel
3d rendering of a red and silver realistic model of a retro rocket stands crashed into a wooden desk on a blue background. Failed launch. Technological progress. Technical mistake.
Duchenne muscular dystrophy
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study
Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit improvement.
May 7, 2026
 · 
3 min read
 · 
Tristan Manalac
Businessman confuse others with jargon in speech bubble dialogue
FDA
Sanofi requests removal of Tzield from CNPV program after Høeg gets involved
Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve Sanofi’s type 1 diabetes drug. It’s far from the first time a political appointee has allegedly meddled in a recent FDA decision.
May 7, 2026
 · 
4 min read
 · 
Heather McKenzie
Concept of business growth,profit, development and success. Young plants increase on sunny background.Growing money,finance and investment
Earnings
Sarepta says to ‘exercise prudence’ in setting expectations for Elevidys’ recovery
Sarepta Therapeutics has put in place several initiatives to help its gene therapy Elevidys return to growth, but recovery will take a long time, according to company executives.
May 7, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS